2025 Volume 47 Issue 1 Pages 1-8
To date, there are few real world data comparing the long-term efficacy of high dose liraglutide in Japanese patients with type 2 diabetes mellitus (T2DM). This study investigated the clinical efficacy and safety of high dose liraglutide in Japanese patients with T2DM in a real-world clinical setting. This retrospective study included 71 patients with T2DM (43 in a high dose liraglutide group and 28 in a control group) who had been using liraglutide at 0.9 mg/day for at least 3 months, and then the dosage was increased to 1.2 mg/day or higher at the physician's discretion to reinforce treatment, and this continued for 12 months. The primary endpoint was the change in HbA1c at 12 months in the high dose liraglutide group. HbA1c significantly decreased from 8.4% to 7.8% in high dose liraglutide group after 12 months and remained unchanged from 7.9% to 7.7% in the control group. Body weight significantly decreased from 75.9 kg to 74.2 kg in the high dose liraglutide group after 12 months. No patient in the high dose liraglutide group had to reduce or discontinue the dose due to side effects. Our study suggests that, in Japanese patients with type 2 diabetes with poorly controlled T2DM in clinical practice, if liraglutide 0.9 mg/day is not effective, high dose liraglutide can be expected to improve HbA1c and decrease body weight with few side effects.
